Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Tislelizumab with Chemotherapy for Nasopharyngeal Carcinoma
The RATIONALE-309 trial demonstrated that tislelizumab plus chemotherapy provided sustained progression-free survival and numerical overall survival improvements compared to placeb
New Protocol: Teclistamab with Daratumumab for Rel/Ref Multiple Myeloma
The study demonstrated significantly longer progression-free survival with teclistamab-daratumumab compared to DPd or DVd, with a hazard ratio of 0.17. The combination also achieve
New Drug: Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm
Pivekimab Sunirine showed high response rates in patients with frontline de novo blastic plasmacytoid dendritic cell neoplasm, with a composite complete response rate of 75% and a
New Reference: Long Term Survival with Nivolumab-Ipilimumab in Advanced RCC
Nivolumab plus ipilimumab demonstrated a significant survival benefit and higher response rates compared to sunitinib for first-line treatment of advanced renal cell carcinoma, wit
New Protocol: Neoadjuvant GOLP for Cholangiocarcinoma
The study demonstrated that neoadjuvant GOLP significantly extended event-free survival compared to the control group in patients with resectable high-risk intrahepatic cholangioca
New Reference: Periop Enfortumab Vedotin and Pembrolizumab for Bladder Cancer
Perioperative enfortumab vedotin and pembrolizumab significantly improved event-free and overall survival compared to surgery alone in muscle-invasive bladder cancer patients ineli
New Protocol: Eflornithine with Lomustine for Recurrent Astrocytoma
The STELLAR trial found that the addition of eflornithine to lomustine significantly improved overall and progression-free survival in patients with IDH-mut grade 3 astrocytoma but
New Protocol: Datopotamab Deruxtecan with Osimertinib for EGFR-Mutated NSCLC
The combination of osimertinib and datopotamab deruxtecan showed clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. The 6 mg/kg
New Indication: Axitinib for Advanced Neuroendocrine Tumors
Axitinib combined with octreotide LAR in patients with advanced progressive extrapancreatic neuroendocrine tumors showed an increase in progression-free survival assessed by blinde
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.